Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9212 |
High Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.913 |
High Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.8994 |
High Similarity |
NPD7808 |
Phase 3 |
0.8935 |
High Similarity |
NPD7251 |
Discontinued |
0.8882 |
High Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.8876 |
High Similarity |
NPD6797 |
Phase 2 |
0.878 |
High Similarity |
NPD7075 |
Discontinued |
0.8757 |
High Similarity |
NPD7054 |
Approved |
0.8706 |
High Similarity |
NPD7472 |
Approved |
0.8688 |
High Similarity |
NPD5403 |
Approved |
0.865 |
High Similarity |
NPD6801 |
Discontinued |
0.8598 |
High Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.8596 |
High Similarity |
NPD7074 |
Phase 3 |
0.8562 |
High Similarity |
NPD5401 |
Approved |
0.8547 |
High Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.8528 |
High Similarity |
NPD4380 |
Phase 2 |
0.85 |
High Similarity |
NPD6799 |
Approved |
0.8483 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.848 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.8471 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.8471 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.8471 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.8434 |
Intermediate Similarity |
NPD5402 |
Approved |
0.84 |
Intermediate Similarity |
NPD8313 |
Approved |
0.84 |
Intermediate Similarity |
NPD8312 |
Approved |
0.8364 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.8363 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.8323 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.8286 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.8274 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.8263 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.8214 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.8193 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.8187 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8166 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.8125 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8125 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.811 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.811 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.8098 |
Intermediate Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.8047 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7988 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7977 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7955 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7953 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7952 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7941 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7937 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7931 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7907 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7888 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.784 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7836 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7831 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7824 |
Intermediate Similarity |
NPD8151 |
Discontinued |
0.7784 |
Intermediate Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.7784 |
Intermediate Similarity |
NPD7874 |
Approved |
0.7772 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7758 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7758 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7709 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7708 |
Intermediate Similarity |
NPD7870 |
Phase 2 |
0.7708 |
Intermediate Similarity |
NPD7871 |
Phase 2 |
0.7697 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7684 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7684 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7684 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7684 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7684 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7684 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7684 |
Intermediate Similarity |
NPD6780 |
Approved |
0.7656 |
Intermediate Similarity |
NPD7696 |
Phase 3 |
0.7656 |
Intermediate Similarity |
NPD7698 |
Approved |
0.7656 |
Intermediate Similarity |
NPD7697 |
Approved |
0.7647 |
Intermediate Similarity |
NPD1653 |
Approved |
0.764 |
Intermediate Similarity |
NPD1240 |
Approved |
0.764 |
Intermediate Similarity |
NPD7784 |
Clinical (unspecified phase) |
0.7629 |
Intermediate Similarity |
NPD7584 |
Approved |
0.7625 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7622 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7617 |
Intermediate Similarity |
NPD8319 |
Approved |
0.7617 |
Intermediate Similarity |
NPD8320 |
Phase 1 |
0.7602 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7598 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.759 |
Intermediate Similarity |
NPD7701 |
Phase 2 |
0.7588 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7584 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7582 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7563 |
Intermediate Similarity |
NPD7783 |
Phase 2 |
0.7563 |
Intermediate Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.7546 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7545 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7528 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7516 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7514 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7488 |
Intermediate Similarity |
NPD8155 |
Clinical (unspecified phase) |
0.7487 |
Intermediate Similarity |
NPD7699 |
Phase 2 |
0.7487 |
Intermediate Similarity |
NPD7700 |
Phase 2 |
0.7475 |
Intermediate Similarity |
NPD7801 |
Approved |
0.7472 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7469 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7459 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7455 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7429 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7425 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7421 |
Intermediate Similarity |
NPD6534 |
Approved |
0.7421 |
Intermediate Similarity |
NPD6535 |
Approved |
0.7416 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7411 |
Intermediate Similarity |
NPD7585 |
Approved |
0.7396 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.738 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7378 |
Intermediate Similarity |
NPD1933 |
Approved |
0.736 |
Intermediate Similarity |
NPD919 |
Approved |
0.736 |
Intermediate Similarity |
NPD7583 |
Approved |
0.7333 |
Intermediate Similarity |
NPD6823 |
Phase 2 |
0.7322 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7312 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7287 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7283 |
Intermediate Similarity |
NPD920 |
Approved |
0.7267 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7262 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7251 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7246 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7243 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7209 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7202 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7195 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7186 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7176 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7176 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7175 |
Intermediate Similarity |
NPD37 |
Approved |
0.717 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7169 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7167 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7151 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7151 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7151 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7112 |
Intermediate Similarity |
NPD7240 |
Approved |
0.711 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7104 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7102 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7102 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7088 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7073 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7069 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7069 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7069 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7066 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7066 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.7041 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7037 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7031 |
Intermediate Similarity |
NPD4287 |
Approved |
0.7024 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7022 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7019 |
Intermediate Similarity |
NPD9717 |
Approved |
0.701 |
Intermediate Similarity |
NPD6212 |
Phase 3 |
0.701 |
Intermediate Similarity |
NPD6214 |
Clinical (unspecified phase) |
0.701 |
Intermediate Similarity |
NPD6213 |
Phase 3 |
0.7006 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD1613 |
Approved |
0.6994 |
Remote Similarity |
NPD3887 |
Approved |
0.6994 |
Remote Similarity |
NPD2354 |
Approved |
0.6988 |
Remote Similarity |
NPD3268 |
Approved |
0.6988 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6984 |
Remote Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.6977 |
Remote Similarity |
NPD2800 |
Approved |
0.6974 |
Remote Similarity |
NPD4363 |
Phase 3 |
0.6974 |
Remote Similarity |
NPD4360 |
Phase 2 |
0.6964 |
Remote Similarity |
NPD230 |
Phase 1 |
0.6964 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6959 |
Remote Similarity |
NPD2344 |
Approved |
0.6957 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6954 |
Remote Similarity |
NPD7440 |
Discontinued |
0.6951 |
Remote Similarity |
NPD2798 |
Approved |
0.6946 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6936 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD1548 |
Phase 1 |
0.6906 |
Remote Similarity |
NPD4288 |
Approved |
0.6905 |
Remote Similarity |
NPD943 |
Approved |
0.6901 |
Remote Similarity |
NPD5404 |
Approved |
0.6901 |
Remote Similarity |
NPD5405 |
Approved |
0.6901 |
Remote Similarity |
NPD5406 |
Approved |
0.6901 |
Remote Similarity |
NPD5408 |
Approved |
0.6898 |
Remote Similarity |
NPD7799 |
Discontinued |
0.689 |
Remote Similarity |
NPD2797 |
Approved |
0.6889 |
Remote Similarity |
NPD6844 |
Discontinued |
0.6881 |
Remote Similarity |
NPD7211 |
Clinical (unspecified phase) |
0.6866 |
Remote Similarity |
NPD7680 |
Approved |
0.6864 |
Remote Similarity |
NPD447 |
Suspended |
0.6864 |
Remote Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.686 |
Remote Similarity |
NPD7930 |
Approved |
0.686 |
Remote Similarity |
NPD2346 |
Discontinued |
0.6842 |
Remote Similarity |
NPD4308 |
Phase 3 |
0.6839 |
Remote Similarity |
NPD7003 |
Approved |
0.6836 |
Remote Similarity |
NPD5049 |
Phase 3 |
0.6822 |
Remote Similarity |
NPD8059 |
Phase 3 |
0.6822
|
Remote Similarity |
NPD8058 |
Clinical (unspecified phase) |